The Jakarta Composite Index (IHSG) closed down 0.84% in the first trading session but foreign investors recorded a net buy of Rp 2.6 trillion across all markets. Bank Central Asia (BBCA) and Bank Rakyat Indonesia (BBRI) were the most purchased stocks by foreign investors. The index experienced a consistent decline towards the end of the first session, with around 418 issuers falling, 288 rising, and 253 remaining unchanged.

This article provides a detailed revenue breakdown for Alnylam Pharmaceuticals Inc (ALNY), categorizing its income by business segments and geographical regions. For FY2025, the company's leading product, AMVUTTRA, contributed 62.30% of revenue, with significant regional revenue coming from the United States (55.67%). The data also includes contributions from other products like GIVLAARI and OXLUMO, as well as revenue from collaborations and royalties, highlighting the diverse sources of the company's financial inflow.

JPMorgan Asset Management is advising investors to maintain positions in riskier assets, such as stocks, for the second half of 2026. The firm believes that robust AI spending, strong consumer resilience, and easing geopolitical tensions will drive economic growth, counteracting concerns about inflation and the Federal Reserve's steady interest rate policy. This outlook suggests confidence in continued market expansion despite recent significant gains.

Humana Inc. has secured a statewide Medicaid contract in Illinois for its HealthChoice Illinois program, expanding its services across all 102 counties. This move reinforces Humana's growing Medicaid presence and comes as the company's shares trade near their 52-week high, with analysts maintaining positive ratings and price targets. Humana is also actively partnering with local organizations to address social determinants of health for Illinois Medicaid members.

Moderna, Inc. announced it will host an Investor Event - Science Day on Thursday, June 25, 2026, at 9:00 AM ET. The event will showcase the company's research and early development programs, highlighting how its mRNA platform, combined with AI and robotics, is driving innovation and expanding into new therapeutic areas. A live webcast will be available on Moderna's investor relations website, with a replay archived for at least 30 days.

Jabil reported better-than-expected fiscal third-quarter results, driven by strong AI infrastructure demand, which led to a significant increase in its AI-related revenue outlook. The company also raised its fiscal 2026 financial guidance, now projecting $35B in net revenue and $12.70 non-GAAP EPS. Despite the positive news, Jabil's shares were largely flat in premarket trading.

Despite a recent stock price dip, EQT Corporation, the largest natural gas producer in the U.S., shows strong potential. The company boasts impressive revenue growth, rising EBITDA margins, and excellent free cash flow margins, indicating a robust business model and strong financial health. These factors suggest EQT is a compelling investment opportunity, particularly after its recent price correction.

Progressive (NYSE: PGR) announced leadership changes, including the planned retirement of Personal Lines President Pat Callahan in January 2027. Lori Niederst will transition to the newly created role of Chief Personal Lines Officer, overseeing Personal Lines and CRM operations, while Heather Day will become the CRM President in July. The company emphasizes a smooth transition due to its focus on employee growth and internal talent development.

Stifel has increased its price target for Paychex Inc. (NASDAQ:PAYX) to $110 from $105, while retaining a Hold rating, citing a positive margin outlook and stable key performance indicators. The firm anticipates mid-single-digit revenue growth and modest margin expansion for fiscal 2027, supported by cost synergy realization and AI adoption. Paychex's strong gross profit margin, consistent dividend payments, and potential undervaluation, as highlighted by InvestingPro, position it as an attractive option for defensive investors.

This article provides a historical overview of dividends and stock splits for Universe Pharmaceuticals Inc (UPC). It notes that the company has distributed no dividends in the past five years and lists several merger-related stock splits with various ratios, predominantly occurring in March 2025 and November 2024. The stock information, including market cap and P/E ratio, is also presented.